Funda Meric-Bernstam, MD
Enriched profileDepartment Chair, Investigational Cancer Therapeutics; Medical Director, Khalifa Institute for Personalized Cancer Therapy; Nellie B. Connally Chair in Breast Cancer; Professor, Breast Surgical Oncology · The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam is Department Chair, Investigational Cancer Therapeutics; Medical Director, Khalifa Institute for Personalized Cancer Therapy; Nellie B. Connally Chair in Breast Cancer; Professor, Breast Surgical Oncology at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 2,643 publications with 108,262 citations (h-index 148); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. Clarivate lists Funda Meric-Bernstam as a Highly Cited Researcher (Clinical Medicine, 2024; Cross-Field, 2019-2021).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Funda Meric-Bernstam, M.D., is Department Chair, Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 2,643 publications with 108,262 citations (h-index 148), centered on Cancer Genomics and Diagnostics, HER2/EGFR in Cancer Research, Lung Cancer Treatments and Mutations. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 20 companies, 10 NIH-funded awards (2001–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Cancer Genomics and Diagnostics
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 20 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 105 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 698.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- PRE-I-SPY Phase I/Ib Oncology Platform Program
Sponsor: QuantumLeap Healthcare Collaborative
- Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 27 Aug 2026
20 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim International GmbHProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- Daiichi Sankyo Inc.Program year20254 payments
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
100%Corticosteroid100%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
10 NIH research awards on record, funded 2001–2026 per NIH RePORTER. The latest:
- Center for Clinical and Translational Sciences
University of Texas Hlth Sci Ctr Houston
FY2026$5,479,769UM1TR004906 - Texas EXperimental Cancer Therapeutics Network - TEX CTN
University of Tx Md Anderson Can Ctr
FY2026$1,519,430UM1CA186688 - Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold
University of Oklahoma Hlth Sciences Ctr
FY2026$579,728R01CA273168
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.
Journal of gynecologic oncology
Clinical Trial2026 - HER2 Positivity as a Prognostic Biomarker and Therapeutic Target in Advanced Biliary Tract Cancer: A Multi-institutional Analysis.
Clinical cancer research
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors1,694 citations2020
- 04PD-L1 Expression in Triple-Negative Breast Cancer1,407 citations2014
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/funda-meric-bernstam-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Funda-Meric-Bernstam
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/christopherrflowersmd_congratulations-to-dr-funda-meric-bernstam-activity-7161254840520638467-rs4L
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/posts/khandan-keyomarsi-05a4a01_funda-meric-bernstam-md-elected-to-national-activity-7254615632178995201-av_s
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/posts/mdandersoncancercenter_dr-funda-meric-bernstam-explains-how-clinical-activity-6791358350312439808-EZF7
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- Department Chair
Investigational Cancer Therapeutics (Phase I Program)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
- Cross-Field201920202021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →meetings.asco.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- Regular Member
Professor (Cancer Biology and Therapeutics and Pharmacology Program), UTHealth Houston Graduate School of Biomedical Sciences
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gsbs.uth.edu ↗ - Member
Clinical Advisory Board, Sutro Biopharma, Inc.
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sutrobio.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urotoday.com ↗
- Video interview
"Trastuzumab Deruxtecan Safety in HER2-Expressing Solid Tumors" -- Oncology Data Advisor, 2023 ASCO Annual Meeting
2023provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncdata.com ↗ - Video
"Funda Meric-Bernstam, MD on HER2-Expressing Solid Tumors: Efficacy and Safety of Trastuzumab Deruxtecan" -- ASCO Post, 2023 ASCO Annual Meeting
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center